rimonabant

(redirected from Acomplia)

rimonabant

A selective cannabinoid-1 receptor blocker that has been shown to reduce body weight and the risk of cardiovascular disease in obese people. The drug has been shown capable of achieving substantial weight loss and reducing cardiovascular risk factors. It has aroused excitement among drug manufacturers who hope it may prove effective in the control of smoking as well as excessive calorie and alcohol intake.
References in periodicals archive ?
Regardless, following the non-launch of Rimonabant (Acomplia and Zimulti), a cannabinoid (CB1) receptor antagonist in 2007 due to potential psychiatric issues, Orlistat remains the only long-term pharmacological agent licensed to treat gross obesity in the UK and U.S.
[6] EPAR, "Acomplia: scientific discussion," European Public Assessment Report EMEA/H/C/666, European Medicines Agency, London, UK, 2006.
Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical's Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the market due to evidence of suicidal thoughts, depression and cardiovascular problems with their long-term use.
Three years ago, 23- year- old Neha ( name changed) convinced her mother that a mild dose of Rimoslim, also known as Acomplia or Rimonabant, would help her drop a dress size.
For example, the Acomplia created by Sanofi-Aventis was withdrawn from the market in September 2008, though its AMM only dated from June 2006.
Major Finding: A clinical trial of rimonabant (Acomplia) was discontinued after an average of 14 months' follow-up because of concerns about suicide and psychiatric problems.
unanimously not to recommend a weight-loss treatment called Acomplia....
The two leading drugs in the market Acomplia (rimonabant; sanofi-aventis) and Meridia (sibutramine; Abbott Laboratories) have both been withdrawn from the European markets because of side effects, and Acomplia has never received regulatory approval in the United States.
The study looked at the use of orlistat (Xenical), sibutramine (Reductil) and rimonabant (Acomplia) in children up to 18 from January 1999 to December 2006.
O Rimonabanto esta indicado como adjuvante a dieta e aos exercicios fisicos para o tratamento de pacientes obesos (indice de massa corporea--IMC maior ou igual a 30kg/[m.sup.2]) ou pacientes com sobrepeso (IMC maior do que 27kg/[m.sup.2]) com fatores de risco associados, como diabetes tipo II e dislipidemia (Acomplia citado por Bertuol, Budel, 2008).
The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. Disponible en: http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/53777708en.pdf [consultado el 02/07/09].